XML 60 R45.htm IDEA: XBRL DOCUMENT v3.3.1.900
BUSINESS COMBINATION AND DIVESTITURE OF ASSETS (Details) - USD ($)
$ in Thousands
12 Months Ended
Mar. 31, 2015
Feb. 12, 2015
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Business Acquisition [Line Items]          
Cash payment     $ 3,938 $ 1,163 $ 0
Acquisition-related contingent consideration     45,267 $ 9,520  
Product rights          
Business Acquisition [Line Items]          
Assets useful life (in years)       16 years  
Asklepion Pharmaceuticals LLC          
Business Acquisition [Line Items]          
Cash payment $ 28,400        
Common stock shares issued (in shares) 661,279        
Value of common stock $ 15,844        
Acquisition-related contingent consideration     $ 39,100    
Discount rate percentage     19.00%    
Fair value of Pediatric Priority Review Voucher 96,250        
Intangible assets acquired 83,200        
Contingent consideration agreement, high amount     $ 16,300    
Net present value of service fees     2,900    
Total payments of service fees     $ 4,000    
Payment period (in years)     4 years    
Deferred tax liability (39,880)        
Assets acquired in business combination $ 88,500        
Utilized tax rate percentage 45.40%        
Purchase price allocation $ 91,284        
Asklepion Pharmaceuticals LLC | Product rights          
Business Acquisition [Line Items]          
Assets useful life (in years) 10 years        
Asklepion Pharmaceuticals LLC | United States | Product rights          
Business Acquisition [Line Items]          
Intangible assets acquired $ 75,900        
Asklepion Pharmaceuticals LLC | International | Product rights          
Business Acquisition [Line Items]          
Intangible assets acquired 7,300        
Asklepion Pharmaceuticals LLC | Definitive Agreement          
Business Acquisition [Line Items]          
Upfront payment   $ 5,000      
Asklepion Pharmaceuticals LLC | Purchase Agreement          
Business Acquisition [Line Items]          
Value of common stock $ 9,000